ArticleDiscover oncology2025
Quercetin suppresses endometrial cancer stem cells via ERα-mediated inhibition of STAT3 signaling.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeted Folate-Chitosan Nanoformulations of Quercetin andPharmaceuticals (Basel, Switzerland) · 2026Article
- A Review of the Potential Therapeutic Benefits of Quercetin for Uterine-Related Conditions.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuercetin, a secondary metabolite derived from plants with both medicinal and edible values, has demonstrated potential in cancer treatment, including endometrial carcinoma. However, its anti-tumor effect on cancer stem-like cells (CSCs), a subpopulation considered to be a major driver of tumor recurrence and metastasis-remain largely unclear.
aimThis study aimed to evaluate the anti-tumor effects of Quercetin by targeting CSCs and suppressing their stemness properties.
methodsCSCs were enriched using serum-free medium and treated with a range concentration of Quercetin. The STAT3/JAK2 signalling was detected by western blot after treatment with Quercetin. The effects of Quercetin on malignant behaviours in CSCs, including proliferation, cell cycle distribution, spheres formation and invasion, were further assessed.
resultsQuercetin treatment inhibited the formation and maintenance of spheres derived from endometrial carcinoma cell lines EMN8 and EMN21.It also downregulated the expression of stemness markers, including ALDH1A1, c-Myc, Nanog, and Oct4.We further revealed that estrogen receptor α (ERα) is critical for mediating the inhibitory effects of Quercetin on stemness and malignant behavior, suggesting that ERα sensitizes CSCs to Quercetin. Quercetin suppressed STAT3/JAK2 phosphorylation and subsequently inhibited the transcriptional activity of STAT3's downstream target gene, Oct4.These inhibitory effects were reversed by the STAT3 activator Colivelin.
conclusionOur findings demonstrate that Quercetin targets the stemness of CSCs in an ERα-dependent manner, highlighting its potential as a promising therapeutic agent against CSCs to improve clinical outcomes in endometrial carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.